{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:57:52Z","timestamp":1776920272108,"version":"3.51.2"},"reference-count":103,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006010","name":"Bayer Schering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ncl.2025.08.004","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T21:51:56Z","timestamp":1757541116000},"page":"91-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Placebo Responses in Trials for Multiple Sclerosis"],"prefix":"10.1016","volume":"44","author":[{"given":"Luana","family":"Gilio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Stampanoni Bassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncl.2025.08.004_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419826547","article-title":"Evolution of clinical trials in multiple sclerosis","volume":"12","author":"Zhang","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"10.1016\/j.ncl.2025.08.004_bib2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ana.1025","article-title":"Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National multiple sclerosis society (USA) task force on placebo-controlled clinical trials in MS","volume":"49","author":"Lublin","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2025.08.004_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.msard.2016.03.019","article-title":"A review of the ethics of the use of placebo in clinical trials for relapsing-remitting multiple sclerosis therapeutics","volume":"7","author":"Solomon","year":"2016","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"10.1016\/j.ncl.2025.08.004_bib4","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1177\/1352458511435715","article-title":"Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis","volume":"18","author":"Nicholas","year":"2012","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.ncl.2025.08.004_bib5","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1177\/1352458513481009","article-title":"Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression","volume":"19","author":"Steinvorth","year":"2013","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.004_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40120-020-00213-4","article-title":"Overview of differences and similarities of published mixed treatment comparisons on pharmaceutical interventions for multiple sclerosis","volume":"9","author":"Sormani","year":"2020","journal-title":"Neurol Ther"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.004_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1352458519845837","article-title":"Real-world studies provide reliable comparisons of disease modifying therapies in MS - no","volume":"26","author":"Sormani","year":"2020","journal-title":"Mult Scler"},{"issue":"19","key":"10.1016\/j.ncl.2025.08.004_bib8","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1113\/JP271322","article-title":"Teaching neurons to respond to placebos","volume":"594","author":"Benedetti","year":"2016","journal-title":"J Physiol"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.004_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10072-018-3613-x","article-title":"Effect of patients\u2019 expectations on clinical response to fampridine treatment","volume":"40","author":"Ladeira","year":"2019","journal-title":"Neurol Sci"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.004_bib10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/cns.12358","article-title":"Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC\/CBD): dimension and possible causes","volume":"21","author":"Di Marzo","year":"2015","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.004_bib11","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/j.pain.0000000000000431","article-title":"Meta-analysis of placebo responses in central neuropathic pain: impact of subject, study, and pain characteristics","volume":"157","author":"Cragg","year":"2016","journal-title":"Pain"},{"issue":"12","key":"10.1016\/j.ncl.2025.08.004_bib12","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1177\/1352458510379246","article-title":"Assessing changes in relapse rates in multiple sclerosis","volume":"16","author":"Inusah","year":"2010","journal-title":"Mult Scler"},{"issue":"10","key":"10.1016\/j.ncl.2025.08.004_bib13","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1177\/1352458511406309","article-title":"Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design","volume":"17","author":"Nicholas","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.ncl.2025.08.004_bib14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2015.00520","article-title":"Infection as an environmental trigger of multiple sclerosis disease exacerbation","volume":"6","author":"Steelman","year":"2015","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.ncl.2025.08.004_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137052","article-title":"Changing EDSS progression in placebo cohorts in relapsing MS: a systematic review and meta-regression","volume":"10","author":"R\u00f6ver","year":"2015","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"10.1016\/j.ncl.2025.08.004_bib16","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0022-510X(11)70007-7","article-title":"Review of methodological issues of clinical trials in multiple sclerosis","volume":"311","author":"Montalban","year":"2011","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.004_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ana.10240","article-title":"Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis","volume":"52","author":"Dalton","year":"2002","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2025.08.004_bib18","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1185\/03007995.2011.591370","article-title":"The changing face of multiple sclerosis clinical trial populations","volume":"27","author":"Uitdehaag","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.ncl.2025.08.004_bib19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamaneurol.2019.0330","article-title":"Changes in the risk of reaching multiple sclerosis disability milestones in recent decades: a nationwide population-based cohort study in Sweden","volume":"76","author":"Beiki","year":"2019","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.004_bib20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/ana.21464","article-title":"Will rogers phenomenon in multiple sclerosis","volume":"64","author":"Sormani","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2025.08.004_bib21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1749-6632.1965.tb20235.x","article-title":"Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation experimental trials in multiple sclerosis","volume":"122","author":"Schumacher","year":"1965","journal-title":"Ann NY Acad Sci"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.004_bib22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2025.08.004_bib23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2025.08.004_bib24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald criteria","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2025.08.004_bib25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.004_bib26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2025.08.004_bib27","author":"Montalban"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.004_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00259-007-0506-2","article-title":"Staging with PET and the \u201cWill Rogers\u201d effect: redefining prognosis and survival in patients with cancer","volume":"35","author":"Basu","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1016\/j.ncl.2025.08.004_bib29","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.neurol.2021.04.006","article-title":"Disease-modifying therapy usage in patients with multiple sclerosis in France: a 6-year population-based study","volume":"177","author":"Leblanc","year":"2021","journal-title":"Rev Neurol (Paris)"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.004_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/01.wco.0000073929.19076.cd","article-title":"Management of multiple sclerosis: current trials and future options","volume":"16","author":"Noseworthy","year":"2003","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2025.08.004_bib31","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1177\/1352458520972557","article-title":"The use and quality of reporting of propensity score methods in multiple sclerosis literature: a review","volume":"28","author":"Karim","year":"2020","journal-title":"Mult Scler"},{"issue":"9","key":"10.1016\/j.ncl.2025.08.004_bib32","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1177\/13524585221085733","article-title":"Recommendations for the use of propensity score methods in multiple sclerosis research","volume":"28","author":"Simoneau","year":"2022","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.ncl.2025.08.004_bib33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.msard.2017.08.003","article-title":"Comparing the efficacy of disease-modifying therapies in multiple sclerosis","volume":"18","author":"Mitsikostas","year":"2017","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.004_bib34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1212\/01.wnl.0000275528.01263.6c","article-title":"Clinical trial outcome in neuropathic pain: relationship to study characteristics","volume":"70","author":"Katz","year":"2008","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ncl.2025.08.004_bib35","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1097\/j.pain.0000000000000333","article-title":"Increasing placebo responses over time in U.S. clinical trials of neuropathic pain","volume":"156","author":"Tuttle","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.ncl.2025.08.004_bib36","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.287.14.1840","article-title":"Placebo response in studies of major depression: variable, substantial, and growing","volume":"287","author":"Walsh","year":"2002","journal-title":"JAMA"},{"issue":"suppl 4","key":"10.1016\/j.ncl.2025.08.004_bib37","first-page":"S7","article-title":"Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain","volume":"65","author":"Dworkin","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2025.08.004_bib38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13063-019-3215-9","article-title":"How context can impact clinical trials: a multi-country qualitative case study comparison of diagnostic biomarker test interventions","volume":"20","author":"Haenssgen","year":"2019","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.004_bib39","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1186\/s13063-024-08623-7","article-title":"Improving measures of context in process evaluations: development and use of the context tracker tool","volume":"25","author":"Busza","year":"2024","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.004_bib40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/bja\/aet126","article-title":"Challenges in design and interpretation of chronic pain trials","volume":"111","author":"Moore","year":"2013","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.ncl.2025.08.004_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103129","article-title":"Ethical considerations in the treatment of multiple sclerosis fatigue","volume":"54","author":"Nourbakhsh","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"10.1016\/j.ncl.2025.08.004_bib42","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1212\/01.WNL.0000158272.27070.6A","article-title":"Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study","volume":"64","author":"Stankoff","year":"2005","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.004_bib43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpainsymman.2004.05.002","article-title":"Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review","volume":"28","author":"Chou","year":"2004","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.ncl.2025.08.004_bib44","article-title":"Anti-spasticity agents for multiple sclerosis","volume":"4","author":"Shakespeare","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.ncl.2025.08.004_bib45","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/1740774512465064","article-title":"Development of the stanford expectations of treatment scale (SETS): a tool for measuring patient outcome expectancy in clinical trials","volume":"9","author":"Younger","year":"2012","journal-title":"Clin Trials"},{"key":"10.1016\/j.ncl.2025.08.004_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1287344","article-title":"Design recommendations for studies that evaluate multiple sclerosis fatigue interventions","volume":"14","author":"Ghajarzadeh","year":"2024","journal-title":"Front Psychiatry"},{"issue":"9","key":"10.1016\/j.ncl.2025.08.004_bib47","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","article-title":"A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols\u2217 (Sativex(\u00ae), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis","volume":"18","author":"Novotna","year":"2011","journal-title":"Eur J Neurol"},{"issue":"24","key":"10.1016\/j.ncl.2025.08.004_bib48","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1200\/JCO.2009.22.3701","article-title":"Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges","volume":"27","author":"Mandrekar","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.004_bib49","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1080\/10543400902802458","article-title":"Clinical trial designs for predictive biomarker validation: one size does not fit all","volume":"19","author":"Mandrekar","year":"2009","journal-title":"J Biopharm Stat"},{"issue":"10","key":"10.1016\/j.ncl.2025.08.004_bib50","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.pain.2012.06.024","article-title":"An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain","volume":"153","author":"Toth","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.ncl.2025.08.004_bib51","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/656582","article-title":"Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation","volume":"2015","author":"Russo","year":"2015","journal-title":"Neural Plast"},{"issue":"11","key":"10.1016\/j.ncl.2025.08.004_bib52","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1007\/s00415-015-7878-1","article-title":"Sativex(\u00ae) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis","volume":"262","author":"Leocani","year":"2015","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.ncl.2025.08.004_bib53","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/nm.2435","article-title":"Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors","volume":"17","author":"Benedetti","year":"2011","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ncl.2025.08.004_bib54","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/scan\/nst079","article-title":"Neurobiology of placebo effects: expectations or learning?","volume":"9","author":"Peci\u00f1a","year":"2014","journal-title":"Soc Cogn Affect Neurosci"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.004_bib55","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/mp.2014.164","article-title":"Molecular mechanisms of placebo responses in humans","volume":"20","author":"Peci\u00f1a","year":"2015","journal-title":"Mol Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.004_bib56","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1212\/NXI.0000000000000048","article-title":"CB1 receptor affects cortical plasticity and response to physiotherapy in multiple sclerosis","volume":"1","author":"Mori","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.004_bib57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000069738","article-title":"The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach","volume":"72","author":"Fava","year":"2003","journal-title":"Psychother Psychosom"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.004_bib58","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3923","article-title":"The placebo response in medicine: minimize, maximize or personalize?","volume":"12","author":"Enck","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.004_bib59","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000332050","article-title":"A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A study)","volume":"81","author":"Fava","year":"2012","journal-title":"Psychother Psychosom"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.004_bib60","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/mp.2013.124","article-title":"FAAH selectively influences placebo effects","volume":"19","author":"Peci\u00f1a","year":"2014","journal-title":"Mol Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.004_bib61","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/JCP.0b013e3181ac4aaf","article-title":"Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder","volume":"29","author":"Leuchter","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.ncl.2025.08.004_bib62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.molmed.2015.02.009","article-title":"Genetics and the placebo effect: the placebome","volume":"21","author":"Hall","year":"2015","journal-title":"Trends Mol Med"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.004_bib63","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1523\/JNEUROSCI.3420-10.2011","article-title":"Predicting individual differences in placebo analgesia: contributions of brain activity during anticipation and pain experience","volume":"31","author":"Wager","year":"2011","journal-title":"J Neurosci"},{"issue":"5661","key":"10.1016\/j.ncl.2025.08.004_bib64","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1126\/science.1093065","article-title":"Placebo-induced changes in FMRI in the anticipation and experience of pain","volume":"303","author":"Wager","year":"2004","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ncl.2025.08.004_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002570","article-title":"Brain connectivity predicts placebo response across chronic pain clinical trials","volume":"14","author":"T\u00e9treault","year":"2016","journal-title":"PLoS Biol"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.004_bib66","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41598-021-04462-7","article-title":"Cortical morphology predicts placebo response in multiple sclerosis","volume":"12","author":"Cherkasova","year":"2022","journal-title":"Sci Rep"},{"issue":"23","key":"10.1016\/j.ncl.2025.08.004_bib67","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/09638280310001608591","article-title":"A review about the impact of multiple sclerosis on health-related quality of life","volume":"25","author":"Benito-Le\u00f3n","year":"2003","journal-title":"Disabil Rehabil"},{"issue":"12","key":"10.1016\/j.ncl.2025.08.004_bib68","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1177\/1352458517729465","article-title":"Clinical outcome measures for progressive MS trials","volume":"23","author":"Ontaneda","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.ncl.2025.08.004_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1407257","article-title":"The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care - updates at the 2023 plenary event","volume":"15","author":"Zaratin","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.ncl.2025.08.004_bib70","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.msard.2019.05.019","article-title":"Review: patient-Reported outcomes in multiple sclerosis care","volume":"33","author":"D'Amico","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ncl.2025.08.004_bib71","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12916-016-0627-1","article-title":"The importance of collecting structured clinical information on multiple sclerosis","volume":"14","author":"Ziemssen","year":"2016","journal-title":"BMC Med"},{"issue":"9","key":"10.1016\/j.ncl.2025.08.004_bib72","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/ene.13339","article-title":"Patient-reported outcomes in multiple sclerosis: a systematic comparison of available measures","volume":"24","author":"Khurana","year":"2017","journal-title":"Eur J Neurol"},{"issue":"Pt 5","key":"10.1016\/j.ncl.2025.08.004_bib73","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The multiple sclerosis impact scale (MSIS-29): a new patient-based outcome measure","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.004_bib74","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1212\/WNL.45.2.251","article-title":"Disease steps in multiple sclerosis: a simple approach to evaluate disease progression","volume":"45","author":"Hohol","year":"1995","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.004_bib75","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/135245859900500406","article-title":"The Guy\u2019s neurological disability scale (GNDS): a new disability measure for multiple sclerosis","volume":"5","author":"Sharrack","year":"1999","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.004_bib76","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol--a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.004_bib77","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/WNL.47.1.129","article-title":"Validation of the functional assessment of multiple sclerosis quality of life instrument","volume":"47","author":"Cella","year":"1996","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.004_bib78","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/135245850100700208","article-title":"Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg quality of life questionnaire in multiple sclerosis (HAQUAMS)","volume":"7","author":"Gold","year":"2001","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.004_bib79","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/135245859900500410","article-title":"Recent developments in the assessment of quality of life in multiple sclerosis (MS)","volume":"5","author":"Fischer","year":"1999","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.004_bib80","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.004_bib81","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1191\/026921501673658108","article-title":"Developing a disease-specific quality of life measure for people with multiple sclerosis","volume":"15","author":"Ford","year":"2001","journal-title":"Clin Rehabil"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.004_bib82","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1352458507080733","article-title":"Validation of the multiple sclerosis international quality of life questionnaire","volume":"14","author":"Simeoni","year":"2008","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.ncl.2025.08.004_bib83","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1524-4733.2010.00767.x","article-title":"International development of the patient-reported outcome indices for multiple sclerosis (PRIMUS)","volume":"13","author":"McKenna","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.ncl.2025.08.004_bib84","series-title":"Development of the adaptive, bilingual multiple sclerosis health resource survey (MS-HRS)","author":"Haase","year":"2018"},{"issue":"5","key":"10.1016\/j.ncl.2025.08.004_bib85","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"10.1016\/j.ncl.2025.08.004_bib86","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s00415-016-8210-4","article-title":"Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ)","volume":"263","author":"Ziemssen","year":"2016","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.004_bib87","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00115-005-1990-x","article-title":"\u201cFatigue\u201d in multiple sclerosis. Development and and validation of the \u201cW\u00fcrzburger Fatigue Inventory for MS\u201d","volume":"77","author":"Flachenecker","year":"2006","journal-title":"Nervenarzt"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.004_bib88","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.60.1.31","article-title":"Measuring the impact of MS on walking ability: the 12-Item MS walking scale (MSWS-12)","volume":"60","author":"Hobart","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.004_bib89","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/occmed\/kqu168","article-title":"The chalder fatigue scale (CFQ 11)","volume":"65","author":"Jackson","year":"2015","journal-title":"Occup Med (Lond)"},{"issue":"12","key":"10.1016\/j.ncl.2025.08.004_bib90","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1177\/1352458509348519","article-title":"The fatigue scale for motor and cognitive functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue","volume":"15","author":"Penner","year":"2009","journal-title":"Mult Scler"},{"issue":"10","key":"10.1016\/j.ncl.2025.08.004_bib91","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Arch Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.ncl.2025.08.004_bib92","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/clinids\/18.Supplement_1.S79","article-title":"Measuring the functional impact of fatigue: initial validation of the fatigue impact scale","volume":"18","author":"Fisk","year":"1994","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.004_bib93","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jval.2018.11.007","article-title":"Development and validation of the FSIQ-RMS: a new patient-reported questionnaire to assess symptoms and impacts of fatigue in relapsing multiple sclerosis","volume":"22","author":"Hudgens","year":"2019","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.ncl.2025.08.004_bib94","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1191\/1352458504ms1098oa","article-title":"Reliable screening for neuropsychological impairment in multiple sclerosis","volume":"10","author":"Benedict","year":"2004","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.004_bib95","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","article-title":"Comparison of beck depression inventories -IA and -II in psychiatric outpatients","volume":"67","author":"Beck","year":"1996","journal-title":"J Pers Assess"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.004_bib96","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF01537606","article-title":"The use of the center for epidemiologic studies depression scale in adolescents and young adults","volume":"20","author":"Radloff","year":"1991","journal-title":"J Youth Adolesc"},{"issue":"6","key":"10.1016\/j.ncl.2025.08.004_bib97","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.ncl.2025.08.004_bib98","series-title":"Inventario per l\u2019ansia di \u00abStato\u00bb e di \u00abTratto\u00bb: nuova versione italiana dello STAI Forma Y: manuale","author":"Pedrabissi","year":"1989"},{"key":"10.1016\/j.ncl.2025.08.004_bib99","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ncl.2025.08.004_bib100","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/B978-0-444-52001-2.00016-9","article-title":"Clinical outcome measures in multiple sclerosis","volume":"122","author":"Uitdehaag","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.ncl.2025.08.004_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.878313","article-title":"The role of remote monitoring in evaluating fatigue in multiple sclerosis: a review","volume":"13","author":"Block","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.ncl.2025.08.004_bib102","series-title":"Comparing medicines to help patients with multiple sclerosis feel less fatigued\u2014the TRIUMPHANT-MS study","author":"Nourbakhsh","year":"2021"},{"key":"10.1016\/j.ncl.2025.08.004_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103753","article-title":"The validity, responsiveness, and score interpretation of the PROMISnq physical function - Multiple sclerosis 15a short form in multiple sclerosis","volume":"62","author":"Kamudoni","year":"2022","journal-title":"Mult Scler Relat Disord"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:31:00Z","timestamp":1772785860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861925000544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0733861925000544"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2025.08.004","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Placebo Responses in Trials for Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2025.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}